AstraZeneca PLC (AZN)vsLivaNova PLC (LIVN)
AZN
AstraZeneca PLC
$160.17
+2.23%
HEALTHCARE · Cap: $252.33B
LIVN
LivaNova PLC
$78.18
0.00%
HEALTHCARE · Cap: $4.50B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 4070% more annual revenue ($61.37B vs $1.47B). AZN leads profitability with a 17.0% profit margin vs 12.8%. LIVN appears more attractively valued with a PEG of 0.93. LIVN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Buy60
out of 100
Grade: C+
LIVN
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+7.7%
Fair Value
$71.98
Current Price
$78.18
$6.20 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Earnings expanding 287.8% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : LIVN
The strongest argument for LIVN centers on EPS Growth, Debt/Equity, PEG Ratio. Revenue growth of 10.8% demonstrates continued momentum. PEG of 0.93 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : LIVN
The primary concerns for LIVN are Altman Z-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while LIVN is a value play — different risk/reward profiles.
LIVN carries more volatility with a beta of 0.87 — expect wider price swings.
LIVN is growing revenue faster at 10.8% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
LIVN scores higher overall (68/100 vs 60/100) and 10.8% revenue growth. AZN offers better value entry with a 18.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?